SOUTH SAN FRANCISCO, Calif. Oct. 17, 2005 (PRIMEZONE) -- Hana Biosciences (AMEX:HBX), a South San Francisco-based biopharmaceutical company focused on advancing cancer care, will present at the 2005 BIO InvestorForum, at 2:40 p.m. on Wednesday, October 19, 2005. The presentation will take place in the Sea Cliff Room at the Palace Hotel on 2 New Montgomery Street, San Francisco, California.
Mark Ahn, Ph.D., President and CEO of Hana Biosciences will provide a comprehensive company overview and an update on the commercialization status of Zensana(r), which is targeted for an early 2007 launch. Hosted by the Biotechnology Industry Organization, the forum showcases the leading growth companies in the lifesciences industry.
A live audio webcast of the presentation can be accessed on the investor relations page of the company's website, www.hanabiosciences.com. An audio replay of the presentation will also be available for 90 days after the conference.
About Hana Biosciences
Hana Biosciences, Inc. (AMEX:HBX) is a South San Francisco, CA-based biopharmaceutical company that acquires, develops, and commercializes innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.
This press release contains forward-looking statements that involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third party researchers to develop its product candidates and its lack of experience in developing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-KSB for the year ended December 31, 2004. Hana assumes no obligation to update these forward-looking statements, except as required by law.